Sarepta Therapeutics (NASDAQ:SRPT) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, April 25th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The company had revenue of $57.30 million during the quarter, compared to analyst estimates of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The firm’s quarterly revenue was up 961.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.71) EPS. On average, analysts expect Sarepta Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Sarepta Therapeutics stock opened at $79.99 on Monday. The company has a market capitalization of $5,197.62, a price-to-earnings ratio of -48.77 and a beta of 1.28. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics has a twelve month low of $28.82 and a twelve month high of $84.37.
TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on Wednesday” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://weekherald.com/2018/04/23/sarepta-therapeutics-srpt-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.